TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65~* For patients younger than 50 years, cons-indication for the use of a standard myeloablative conditioning (history of hematopoietic stem cell transplantation autologous or allogeneic, or the presence of co-morbidities or medical history making prohibitive in terms toxicity using chemotherapy and / or high dose radiotherapy as judged by the referring physician) - MDS, ALL or AML at high risk, WHO THE biphenotypic-Score \<2~* Any primary diagnosis of high-risk MDS/AML or ALL eligible for a treatment by reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-SCT)~* Suitable donor available (related or matched unrelated)~* Cardiac: LV Ejection Fraction ≥ 50% by MUGA or Echocardiogram.~* Pulmonary: FEV1 and FVC ≥ 50% predicted, and DLCO (corrected for hemoglobin) ≥ 50% of predicted~* Adequate renal and hepatic function~* Performance status: Karnofsky ≥ 70%~* Informed consent signed by patient prior to enrolment~Exclusion Criteria:~* Age \<18~* Age \>65~* Known hypersensitivity to clofarabine or excipients- Other hematologic malignancies than ALL, AML and MDS~* Patients with prior standard allogeneic HSCT with grade \> 2 aGvHD~* Prior standard allogeneic transplantation if \< 2 months~* Contra-indication to one of the drug of the RIC regimen .~* Patient with \> 3 treatment lines prior to inclusion~* Pregnant or lactating females~* Patient HIV+, Hep B+, Hep C+- Uncontrolled systemic infection~* Performance Status Score ECOG \> 2- Known central nervous system involvement with AML or ALL- Uncontrolled active infection of any kind or bleeding~* Any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo the agents included in the conditioning regimen.~* For patients younger than 50 years, possibly indicating a standard myeloablative conditioning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical and Chemical Study of Atherosclerosis Mechanisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent form~* dyslipidemia (HDL \<1.0 mmol / l, triglycerides (TG) in plasma ≥ 1,7 mmol / l or cholesterol ≥ 5,6 mmol /l)~* waist circumference ≥ 94.0 cm in men or ≥ 80,0 cm in women,~* BP ≥140/95 mm Hg or a patient is taking antihypertensive medications,~* fasting glucose ≥ 6,1 mmol / l or the patient is taking hypoglycemic agents,~* the possibility of treatment for 6 months and follow-up for 1 year~Exclusion Criteria:~* Absence of consent form~* Non-compliance of patient to necessary recommendations.~* The presence of mental illness.~* Complete immobilization of a patient (paresis, and paralysis).

- Gender: ALL
- Minimum Age: 26 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Conventional treatment (Type: ACTIVE_COMPARATOR): Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.
- Weight loss treatment (Type: EXPERIMENTAL): Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Subjects with hypertension and hyperlipidemia~Exclusion Criteria:~1. Patients with known or suspected secondary hypertension~2. Other exclusions applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination drug:Temisartan+Amlodipine+Rosuvastatin (Type: EXPERIMENTAL): 60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks.
- Temisartan+Amlodipine (Type: ACTIVE_COMPARATOR): 60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks.
- Temisartan+Rosuvastatin (Type: ACTIVE_COMPARATOR): 60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: c-Met Second-Line Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed HCC~* Child Pugh Class A liver function score~* For Phase 2 only: MET+ status~* Male or female, 18 years of age or older~* Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (inclusive)~* Availability of a pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) taken after the subject has discontinued sorafenib and within 28 days before the day of first dosing with MSC2156119J. From the pretreatment biopsy either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with tumor tissue (preferred) or at least 15 unstained slides must be sent to the central laboratory prior to enrollment. An associated pathology report must also be sent with the sample~* Previously treated with sorafenib for greater than or equal to 4 weeks and discontinued sorafenib treatment at least 14 days prior to Day 1 due to either intolerance or radiographic progression~* Signed and dated informed consent indicating that the subject (or legally acceptable representative if applicable by local laws) has been informed of all the pertinent aspects of the trial prior to enrollment~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures~* Life expectancy of at least 3 months as judged by the investigator~Exclusion Criteria:~* Prior systemic anticancer treatment for advanced HCC (except for sorafenib as described in the inclusion criteria)~* Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met pathway~* Local-regional therapy within 4 weeks before Day 1~* Impaired cardiac function~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: Tepotinib 300 mg (Type: EXPERIMENTAL): None
- Phase 1b: Tepotinib 500 mg (Type: EXPERIMENTAL): None
- Phase 2: Tepotinib 500 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers~* BMI between 18.5 and 29.9 kg/m2~* weighing between 55 and 95 kg~* willing to use reliable contraception~* able to give fully informed written consent.~Exclusion Criteria:~* Pregnant or lactating woman, or sexually active woman of child-bearing potential not using highly effective contraception~* clinically relevant abnormal medical history, surgery or concurrent medical condition; acute or chronic illness~* clinically significant QT/QTc interval prolongation at Baseline~* history of drug-induced or risk factors for Torsade de Pointes~* any contraindication to moxifloxacin~* severe adverse reaction to any drug or sensitivity to the trial medication or its components~* significant food allergy; use of vitamins, herbal medicines, prescription or over-the-counter medication (with the exception of paracetamol \[acetaminophen\] and oral contraceptives for women) within 20 days or 6 half-lives before first dose of trial medication~* participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 mL blood, within the 3 months before first dose of trial medication~* drug or alcohol abuse; smoking of more than 5 cigarettes, 1 cigars or 1 pipes daily~* regular consumption of more than 5 cups of caffeinated drinks per day~* positive test for hepatitis A, B \& C, HIV~* objection by a General Practitioner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Imeglimin therapeutic dose (Type: EXPERIMENTAL): Tablet, oral, single dose
- Imeglimin supratherapeutic dose (Type: EXPERIMENTAL): Tablet, oral, single dose
- Placebo (Type: PLACEBO_COMPARATOR): Tablet, oral, single dose
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Tablet, oral, single dose (400 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Relapsed and/or refractory myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that meets certain criteria for prior treatments~* Have acceptable circulating blasts count~* Have clinically acceptable laboratory blood and urine test results~* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~* Be able to swallow oral medications~* Have a life expectancy of 3 months or more~* Agree to use highly effective means of contraception during a defined period~* Negative serum pregnancy test before the start of the study drugs~* Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, provide a blood and bone marrow sample for genetic testing and agree to return for the required assessments~Exclusion Criteria:~* Have received cancer therapies within 14 days or 5 half-lives (whichever is shorter) prior to first dose of study drug or have not recovered from toxicities from prior treatments~* Not recovered from toxicities related to allogeneic transplant~* Known active extramedullary central nervous system (CNS) AML~* Secondary cancer needing therapy with exceptions~* Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection~* Known significant mental illness or other condition that may affect the ability to follow the requirements of the study~* Have a chronic infection~* Have uncontrolled severe hypertension~* Have symptomatic congestive heart failure~* Have active angina pectoris or recent myocardial infarction~* Have chronic atrial fibrillation or unacceptable QTc~* Have had major surgery within 21 days of starting therapy~* Have additional uncontrolled serious medical or psychiatric illness~* Have any medical condition that would affect taking the study drug~* Receiving treatment with full dose warfarin~* Receiving treatment with drugs not allowed in this study~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CFI-400945 (Type: EXPERIMENTAL): CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oracea Soolantra Association in Participants With Severe Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject age ≥ 18 years or older;~* Subject with a minimum of 20 but not more than 70 inflammatory lesions (papules and pustules) of rosacea on the face at Baseline visit;~* Subject with severe rosacea with papulopustular lesions (according to the Investigator's Global Assessment (IGA) score rated 4);~* Female subjects of childbearing potential with a negative urine pregnancy test (UPT);~* Female subjects of childbearing potential must practice a highly effective method of contraception during the study.~Exclusion Criteria:~* Subjects with particular forms of rosacea or other concomitant facial dermatoses that may be confounded with rosacea;~* Subjects with more than 2 nodules of rosacea on the face;~* Subjects with any uncontrolled chronic or serious disease or medical condition that may either interfere with the interpretation of the clinical trial results, or with optimal participation in the study or would present a significant risk to the subject;~* Subjects with known or suspected allergies or sensitivities to any component of the investigational and non-investigational products, including the active ingredients doxycycline and ivermectin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivermectin 1% cream + Doxycycline 40 mg MR capsules (Type: EXPERIMENTAL): None
- Ivermectin 1% cream + Oral placebo capsules (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Technology Enhanced Community Health Nursing (TECH-N) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild-moderate PID~* Outpatient treatment disposition~* Permanently reside in the Baltimore Metropolitan area~* Willing to sign informed consent \& be randomized~Exclusion Criteria:~* Pregnant~* Concurrent diagnosis of Sexual Assault~* Unable to communicate/complete study procedures

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- TECH-N (Type: EXPERIMENTAL): Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
- Control (Type: NO_INTERVENTION): Participants receive enhanced standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* JNCL as determined by a characteristic clinical presentation and confirmatory genetic evidence.~* Able to walk 10 feet without assistance beyond that required due to vision impairment.~* Subjects with local treating clinician (pediatrician or neurologist) willing to conduct the trial according to the protocol, good clinical practice, and applicable regulations.~* Subjects with a parent/legal guardian willing to accompany them to all study visits, oversee study drug compliance, and monitor and report to local treating clinician/investigator and the URBC investigative personnel any signs of adversity.~Exclusion Criteria:~* Inability to tolerate oral administration of medications~* Concomitant medical condition, which, in the opinion of the local treating clinician, the parent(s)/guardian, or the URBC study investigator would place the child at greater than acceptable risk from: 1) travel by plane or car to the URBC on four occasions over the course of 22 weeks, 2) exposure to mycophenolate mofetil at protocol defined dosages for periods up to 8 weeks.~* Anticipated inability of the child (on the part of the investigator, parent/guardian, or URBC study personnel) to comply with the rigors of the protocol..~* Use of disallowed concomitant medications.~* Administration of immunosuppressive medications~* History of any prior exposure to mycophenolate mofetil~* History of hypersensitivity to mycophenolate mofetil, or any other component of the product~* History of frank gastrointestinal hemorrhage, ulceration, or melena~* White blood cell count \< 3000/μL, absolute neutrophil count (ANC) \< 1500/μL, hemoglobin \< 10g/dL, or thrombocytopenia \<100,000/μL.~* Abnormal liver function (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or bilirubin greater than 3 times the upper limit of normal)~* Pregnancy or vulnerability to engage in sexual intercourse based on report of the parent/guardian, judgment of the local treating clinician/investigator or judgment of the URBC study personnel.~* Positive Tuberculosis test~* Immunizations not up to date for age according to Centers for Disease Control guidelines

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil (Type: ACTIVE_COMPARATOR): None
- Placebo liquid (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give written informed consent and comply with study requirements~* Patient who speak English~Exclusion Criteria:~* Presence or history of liver, cardiovascular, rheumatologic, cancer or renal disease.~* Current treatment with any vasodilator therapy~* Systolic blood pressure of less than 90 mmHg~* History of radial artery catheterization within the previous year~* Absence of radial artery blood flow in one or both arms~* Pregnancy.~* Active infection~* Staff members of the Cardiac Catheterization Laboratory.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Dose Test 15mg NTG (Type: EXPERIMENTAL): Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1
- Dose Test 30mg NTG (Type: EXPERIMENTAL): Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1
- Combination Test 20mg Lidocaine (Type: EXPERIMENTAL): Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the other wrist, at Visit 2
- Combination Test 40mg Lidocaine (Type: EXPERIMENTAL): Lidocaine 40mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 40mg + placebo applied to the other wrist, at Visit 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of active atopic dermatitis (AD) with at least 6 month history prior to Screening and that has been clinically stable for 1 month.~* Investigator's Static Global Assessment (ISGA) of 2 (mild) or 3 (moderate) at Baseline.~* Body surface area (BSA) covered with AD of at least 0.5% and no more than 10% at Baseline, calculation excluding face, scalp, axilla, genitals, groin area, palms, back of the hands, and soles.~* Two lesions of AD at least 3 cm x 3 cm in size and at least 5 cm apart, with identical Lesion ISGA score of greater than/equal to 3.~Exclusion Criteria:~* Clinically infected AD or requires high potency topical corticosteroids or systemic (oral/injectable) corticosteroids to manage AD.~* History of angioedema or anaphylaxis to topical products or known sensitivity to components of crisaborole ointment 2%.~* History of cancer (except squamous or basal cell carcinoma or carcinoma in situ of the skin).~* Previous treatment with any topical or systemic PDE4 inhibitor unless stopped for the reason of lack of efficacy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crisaborole ointment (Type: EXPERIMENTAL): None
- Placebo ointment (vehicle) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete